{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:41:09Z","timestamp":1767796869234,"version":"3.49.0"},"reference-count":54,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Inside CKD aims to assess the burden of chronic kidney disease (CKD) and the cost-effectiveness of screening programmes in Belgium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Microsimulation-based modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Data derived from national statistics and key literature from Belgium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Virtual populations of \u226510\u2009million individuals, representative of Belgian populations of interest, were generated based on published data and cycled through the Inside CKD model. Baseline input data included age, estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (UACR) and CKD status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measures<\/jats:title>\n                    <jats:p>Outcomes included the clinical and economic burden of CKD during 2022\u20132027 and the cost-effectiveness of two different CKD screening programmes (one UACR measurement and two eGFR measurements or only two eGFR measurements, followed by renin-angiotensin-aldosterone system inhibitor treatment in newly diagnosed eligible patients). The economic burden estimation included patients diagnosed with CKD stages 3\u20135; the screening cost-effectiveness estimation included patients aged \u226545 years with no CKD diagnosis and high-risk subgroups (with cardiovascular disease, hypertension, type 2 diabetes or aged \u226565 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2022 and 2027, CKD prevalence is estimated to remain stable and substantial at approximately 1.66\u2009million, with 69.9% undiagnosed. The total healthcare cost of patients diagnosed with CKD is expected to remain stable at approximately \u20ac2.15\u2009billion per year. The one UACR, two eGFR measurement screening programme was cost-effective in all populations, with an incremental cost-effectiveness ratio of \u20ac3623 per quality-adjusted life year (QALY) gained in those aged \u226545 years, well below the estimated willingness-to-pay threshold of \u20ac43 839 per QALY gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Without changes to current practice, the disease burden of CKD in Belgium is predicted to remain substantial over the next few years. This highlights the need for timely diagnosis of CKD and demonstrates that, in line with guideline recommendations, implementing a CKD screening programme involving UACR and eGFR measurements followed by treatment would be cost-effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098420","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:05:11Z","timestamp":1765782311000},"page":"e098420","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Microsimulation modelling to predict the burden of CKD and the cost-effectiveness of timely CKD screening in Belgium: results from the Inside\n                    <b\/>\n                    CKD study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2533-1669","authenticated-orcid":false,"given":"Rucha","family":"Vadia","sequence":"first","affiliation":[{"name":"AstraZeneca BeLux, Groot-Bijgaarden, Flanders, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eef","family":"Vandendriessche","sequence":"additional","affiliation":[{"name":"AstraZeneca BeLux, Groot-Bijgaarden, Flanders, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elien","family":"Mahieu","sequence":"additional","affiliation":[{"name":"AZ Glorieux, Ronse, East Flanders, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Meeus","sequence":"additional","affiliation":[{"name":"AZ Groeninge, Kortrijk, West Flanders, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gijs","family":"Van Pottelbergh","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, KU Leuven, Leuven, Flanders, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Jouret","sequence":"additional","affiliation":[{"name":"CHU de Li\u00e8ge, Li\u00e8ge, Wallonia, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Retat","sequence":"additional","affiliation":[{"name":"AstraZeneca, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Card-Gowers","sequence":"additional","affiliation":[{"name":"HealthLumen, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[{"name":"Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Vankeirsbilck","sequence":"additional","affiliation":[{"name":"AstraZeneca BeLux, Groot-Bijgaarden, Flanders, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose","family":"Garcia Sanchez","sequence":"additional","affiliation":[{"name":"AstraZeneca, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"2026010703464440000_15.12.e098420.1","doi-asserted-by":"crossref","unstructured":"Sundstr\u00f6m J , Bodegard J , Bollmann A , et al . Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Health Eur 2022;20. doi:10.1016\/j.lanepe.2022.100438","DOI":"10.1016\/j.lanepe.2022.100438"},{"key":"2026010703464440000_15.12.e098420.2","first-page":"21","article-title":"Chronic kidney disease: identification and management in primary care","volume":"7","author":"Fraser","year":"2016","journal-title":"Pragmat Obs Res"},{"key":"2026010703464440000_15.12.e098420.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.10.003"},{"key":"2026010703464440000_15.12.e098420.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02608-9"},{"key":"2026010703464440000_15.12.e098420.5","doi-asserted-by":"crossref","unstructured":"Mullins CD , Pantalone KM , Betts KA , et al . CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes. Kidney Med 2022;4. doi:10.1016\/j.xkme.2022.100532","DOI":"10.1016\/j.xkme.2022.100532"},{"key":"2026010703464440000_15.12.e098420.6","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"2026010703464440000_15.12.e098420.7","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int Suppl"},{"key":"2026010703464440000_15.12.e098420.8","doi-asserted-by":"crossref","unstructured":"Chadban S , Ar\u0131c\u0131 M , Power A , et al . Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. EClinicalMedicine 2024;72. doi:10.1016\/j.eclinm.2024.102615","DOI":"10.1016\/j.eclinm.2024.102615"},{"key":"2026010703464440000_15.12.e098420.9","doi-asserted-by":"crossref","unstructured":"Cleemput I , Beguin C , Kethulle Y , et al . Belgian healthcare knowledge centre (kce). report 124c: organisation and financing of chronic dialysis in belgium. 2010. Available: https:\/\/kce.fgov.be\/sites\/default\/files\/2021-11\/d20101027313.pdf [Accessed 17 Dec 2024].","DOI":"10.57598\/R124C"},{"key":"2026010703464440000_15.12.e098420.10","unstructured":"Meeus P , Dalcq V , Swine B , et al . Chronic dialysis - analysis of the distribution of medical practice in belgium, in terms of volume and expenditure per patient and per insured (distribution, occurrence, trends by region, province and district), for the year 2023. 2024. Available: https:\/\/www.healthybelgium.be\/en\/medical-practice-variations\/urinary-system\/chronic-dialysis#key-figures [Accessed 17 Dec 2024]."},{"key":"2026010703464440000_15.12.e098420.11","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2013.79"},{"key":"2026010703464440000_15.12.e098420.12","doi-asserted-by":"crossref","unstructured":"Edmonston D , Lydon E , Mulder H , et al . Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes. JAMA Netw Open 2024;7. doi:10.1001\/jamanetworkopen.2024.18808","DOI":"10.1001\/jamanetworkopen.2024.18808"},{"key":"2026010703464440000_15.12.e098420.13","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.121.17323"},{"key":"2026010703464440000_15.12.e098420.14","doi-asserted-by":"crossref","unstructured":"Chu CD , Xia F , Du Y , et al . Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease. JAMA Netw Open 2023;6. doi:10.1001\/jamanetworkopen.2023.26230","DOI":"10.1001\/jamanetworkopen.2023.26230"},{"key":"2026010703464440000_15.12.e098420.15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12325-022-02353-5","article-title":"Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD","volume":"40","author":"Tangri","year":"2023","journal-title":"Adv Ther"},{"key":"2026010703464440000_15.12.e098420.16","doi-asserted-by":"crossref","unstructured":"Chertow GM , Correa-Rotter R , Eckardt K-U , et al . Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. EClinicalMedicine 2024;72. doi:10.1016\/j.eclinm.2024.102614","DOI":"10.1016\/j.eclinm.2024.102614"},{"key":"2026010703464440000_15.12.e098420.17","doi-asserted-by":"crossref","unstructured":"Cusick MM , Tisdale RL , Chertow GM , et al . When to Start Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis. JAMA Health Forum 2024;5. doi:10.1001\/jamahealthforum.2024.3892","DOI":"10.1001\/jamahealthforum.2024.3892"},{"key":"2026010703464440000_15.12.e098420.18","unstructured":"United Nations . World population prospects 2019. 2019. Available: https:\/\/population.un.org\/wpp2019\/Download\/Standard\/Population\/ [Accessed 10 Dec 2024]."},{"key":"2026010703464440000_15.12.e098420.19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ckj\/sfab046","article-title":"Methods and rationale of the DISCOVER CKD global observational study","volume":"14","author":"Pecoits-Filho","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026010703464440000_15.12.e098420.20","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1007\/s12325-024-02913-x","article-title":"Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort","volume":"41","author":"Heerspink","year":"2024","journal-title":"Adv Ther"},{"key":"2026010703464440000_15.12.e098420.21","unstructured":"NHS digital . Health survey for England. 2016. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/health-survey-for-england-2016 [Accessed 10 Dec 2024]."},{"key":"2026010703464440000_15.12.e098420.22","unstructured":"International Monetary Fund . World economic outlook report 2022. 2022. Available: https:\/\/www.imf.org\/en\/Publications\/WEO\/Issues\/2022\/10\/11\/world-economic-outlook-october-2022 [Accessed 27 Feb 2023]."},{"key":"2026010703464440000_15.12.e098420.23","unstructured":"Institut scientifique de sant\u00e9 publique . Contacts avec le m\u00e9decin g\u00e9n\u00e9raliste, belgique 2008. 2008. Available: https:\/\/www.wiv-isp.be\/epidemio\/epifr\/CROSPFR\/HISFR\/his08fr\/r3\/3_contactsmedecingeneraliste_gp_report3_fr.pdf [Accessed 30 May 2022]."},{"key":"2026010703464440000_15.12.e098420.24","doi-asserted-by":"crossref","unstructured":"Begos D , Milojkovic B . MO382: Validation of a Handheld Point-Of-Care Creatinine\/EGFR Meter for Evaluating Renal Function. Nephrol Dial Transplant 2022;37. doi:10.1093\/ndt\/gfac069.015","DOI":"10.1093\/ndt\/gfac069.015"},{"key":"2026010703464440000_15.12.e098420.25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010007"},{"key":"2026010703464440000_15.12.e098420.26","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-1-8"},{"key":"2026010703464440000_15.12.e098420.27","doi-asserted-by":"crossref","unstructured":"Van den Wyngaert I , Mamouris P , Vaes B , et al . An exploration of under-registration of chronic kidney disease stages 3-5 in Belgian general practices using logistic regression. PLoS ONE 2022;17. doi:10.1371\/journal.pone.0279291","DOI":"10.1371\/journal.pone.0279291"},{"key":"2026010703464440000_15.12.e098420.28","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12325-020-01607-4","article-title":"Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review","volume":"38","author":"Darlington","year":"2021","journal-title":"Adv Ther"},{"key":"2026010703464440000_15.12.e098420.29","doi-asserted-by":"crossref","unstructured":"Devos C , Cordon A , Lef\u00e8vre M , et al . Report 313c: performance of the belgian health system - report 2019. 2019. Available: https:\/\/kce.fgov.be\/sites\/default\/files\/2021-12\/KCE_313C_Performance_Belgian_health_system_Report.pdf [Accessed 10 Dec 2024].","DOI":"10.57598\/R313C"},{"key":"2026010703464440000_15.12.e098420.30","first-page":"25","article-title":"The importance of early identification of chronic kidney disease","volume":"108","author":"Whaley-Connell","year":"2011","journal-title":"Mo Med"},{"key":"2026010703464440000_15.12.e098420.31","first-page":"93","article-title":"Advancing in the management of chronic kidney disease: the results of implementing a quick resolution consultation","volume":"33","author":"Torregrosa-Maicas","year":"2013","journal-title":"Nefrologia"},{"key":"2026010703464440000_15.12.e098420.32","unstructured":"Pottelbergh G , Avonts M , Cloetens H , et al . Chronische nierinsuffici\u00ebntie. 2012. Available: https:\/\/www.domusmedica.be\/sites\/default\/files\/Richtlijn%20Chronische%20Nierinsuffici%C3%ABntie_0.pdf [Accessed 11 Dec 2024]."},{"key":"2026010703464440000_15.12.e098420.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.012"},{"key":"2026010703464440000_15.12.e098420.34","doi-asserted-by":"crossref","unstructured":"Christofides EA , Desai N . Optimal Early Diagnosis and Monitoring of Diabetic Kidney Disease in Type 2 Diabetes Mellitus: Addressing the Barriers to Albuminuria Testing. J Prim Care Community Health 2021;12. doi:10.1177\/21501327211003683","DOI":"10.1177\/21501327211003683"},{"key":"2026010703464440000_15.12.e098420.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-024-03466-5","article-title":"Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?","volume":"25","author":"Farrell","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026010703464440000_15.12.e098420.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.17002"},{"key":"2026010703464440000_15.12.e098420.37","unstructured":"World Health Organization . Screening programmes: a short guide increase effectiveness, maximize benefits and minimize harm. 2020. Available: https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289054782 [Accessed 10 Dec 2024]."},{"key":"2026010703464440000_15.12.e098420.38","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.kint.2023.03.009","article-title":"Perspectives on early detection of chronic kidney disease: the facts, the questions, and a proposed framework for 2023 and beyond","volume":"103","author":"Levin","year":"2023","journal-title":"Kidney Int"},{"key":"2026010703464440000_15.12.e098420.39","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3228"},{"key":"2026010703464440000_15.12.e098420.40","doi-asserted-by":"crossref","unstructured":"Kairys P , Frese T , Voigt P , et al . Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany. PLoS ONE 2022;17. doi:10.1371\/journal.pone.0262227","DOI":"10.1371\/journal.pone.0262227"},{"key":"2026010703464440000_15.12.e098420.41","doi-asserted-by":"crossref","unstructured":"Pouwels XGLV , van Mil D , Kieneker LM , et al . Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease. EClinicalMedicine 2024;68. doi:10.1016\/j.eclinm.2023.102414","DOI":"10.1016\/j.eclinm.2023.102414"},{"key":"2026010703464440000_15.12.e098420.42","doi-asserted-by":"crossref","unstructured":"Yeo SC , Wang H , Ang YG , et al . Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review. Clin Kidney J 2024;17. doi:10.1093\/ckj\/sfad137","DOI":"10.1093\/ckj\/sfad137"},{"key":"2026010703464440000_15.12.e098420.43","doi-asserted-by":"crossref","unstructured":"van Mil D , Pouwels XGLV , Heerspink HJL , et al . Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps. Clin Kidney J 2024;17. doi:10.1093\/ckj\/sfad254","DOI":"10.1093\/ckj\/sfad254"},{"key":"2026010703464440000_15.12.e098420.44","doi-asserted-by":"crossref","unstructured":"D\u0105bek B , Dybiec J , Fr\u0105k W , et al . Novel Therapeutic Approaches in the Management of Chronic Kidney Disease. Biomedicines 2023;11. doi:10.3390\/biomedicines11102746","DOI":"10.3390\/biomedicines11102746"},{"key":"2026010703464440000_15.12.e098420.45","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026010703464440000_15.12.e098420.46","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"2026010703464440000_15.12.e098420.47","first-page":"476","article-title":"SGLT2 inhibitors : on the borders of diabetology, cardiology, nephrology and\u2026 primary care","volume":"78","author":"Scheen","year":"2023","journal-title":"Rev Med Liege"},{"key":"2026010703464440000_15.12.e098420.48","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026010703464440000_15.12.e098420.49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026010703464440000_15.12.e098420.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2026010703464440000_15.12.e098420.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"2026010703464440000_15.12.e098420.52","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03790322"},{"key":"2026010703464440000_15.12.e098420.53","doi-asserted-by":"crossref","unstructured":"McEwan P , Davis JA , Gabb PD , et al . Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J 2024;17. doi:10.1093\/ckj\/sfae025","DOI":"10.1093\/ckj\/sfae025"},{"key":"2026010703464440000_15.12.e098420.54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13696998.2024.2357041","article-title":"Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom","volume":"27","author":"Ramos","year":"2024","journal-title":"J Med Econ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:48:13Z","timestamp":1767786493000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,14]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2024-098420"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098420","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}